This brand name is authorized in France, Tunisia
The drug LYSANXIA contains one active pharmaceutical ingredient (API):
|
1
Prazepam
UNII Q30VCC064M - PRAZEPAM
|
|
Prazepam is a benzodiazepine derivative and has depressant effects on the central nervous system. Benzodiazepines act at the level of the limbic, thalamic, and hypothalamic regions of the CNS and can produce any level of CNS depression required including sedation, hypnosis, skeletal muscle relaxation, and anticonvulsant activity. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N05BA11 | Prazepam | N Nervous system → N05 Psycholeptics → N05B Anxiolytics → N05BA Benzodiazepine derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: FR | Base de données publique des médicaments | Identifier(s): 60534076, 62949690, 69434084 |
| Country: TN | Direction de la Pharmacie et du Médicament | Identifier(s): 7343021, 7343031 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
